Depomed (NASDAQ:DEPO) SVP Matthew M. Gosling sold 19,674 shares of the business’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $7.07, for a total transaction of $139,095.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Matthew M. Gosling also recently made the following trade(s):
Get Depomed alerts:
On Wednesday, March 7th, Matthew M. Gosling sold 45,519 shares of Depomed stock. The shares were sold at an average price of $6.58, for a total transaction of $299,515.02.
Depomed opened at $7.58 on Friday, Marketbeat Ratings reports. The company has a quick ratio of 0.73, a current ratio of 0.75 and a debt-to-equity ratio of 2.55. The firm has a market cap of $478.18 million, a price-to-earnings ratio of -6.02 and a beta of 1.22. Depomed has a fifty-two week low of $7.43 and a fifty-two week high of $7.53.
Depomed (NASDAQ:DEPO) last posted its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.69. The company had revenue of $128.40 million during the quarter, compared to analysts’ expectations of $65.77 million. Depomed had a negative net margin of 10.02% and a negative return on equity of 15.74%. The firm’s revenue for the quarter was up 41.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.07 earnings per share. equities research analysts predict that Depomed will post -1.1 EPS for the current year.
Several research firms recently issued reports on DEPO. Piper Jaffray reiterated a “hold” rating and issued a $8.00 target price on shares of Depomed in a research note on Thursday, March 1st. BidaskClub upgraded shares of Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Roth Capital set a $10.00 price objective on shares of Depomed and gave the stock a “buy” rating in a research report on Friday, March 2nd. ValuEngine cut shares of Depomed from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Mizuho restated a “buy” rating and set a $9.00 price objective on shares of Depomed in a research report on Friday, March 23rd. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $8.00.
Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of Depomed in the fourth quarter valued at about $127,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Depomed in the fourth quarter valued at about $131,000. ClariVest Asset Management LLC acquired a new stake in shares of Depomed in the first quarter valued at about $108,000. MANA Advisors LLC acquired a new stake in shares of Depomed in the fourth quarter valued at about $148,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Depomed in the fourth quarter valued at about $155,000. Institutional investors own 94.38% of the company’s stock.
Depomed Company Profile
Depomed, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.